![FDA, FTC and DOJ Enforcement of Medical Device Regulations FDA, FTC and DOJ Enforcement of Medical Device Regulations](https://www.fdanews.com/ext/resources/Book-Covers-2/BFFDEMDR-COVER.png?height=200&t=1685733565&width=200)
Home » Teva Launches Generic Uceris Extended-Release Tablets
Teva Launches Generic Uceris Extended-Release Tablets
![Teva.gif](https://www.fdanews.com/ext/resources/test/Drug-Images2/Teva.gif?t=1579040955&width=430)
Teva launched its generic version of Uceris (budesonide) extended-release tablets in the U.S.
The drug, manufactured by Salix Pharmaceuticals, is a glucocorticosteroid indicated for remission in patients with active mild-to-moderate ulcerative colitis.
“The launch of generic budesonide extended-release tablets signals an important addition to Teva’s portfolio,” said Brendan O’Grady, head of Teva North America Commercial.
Uceris had annual sales of approximately $196 million in the U.S. as of May 2018.
Upcoming Events
-
21Oct